Department of Neurosurgery, Osaka University Graduate School of Medicine, Suita, Japan.
Department of Neurosurgery, Osaka University Graduate School of Medicine, Suita, Japan.
World Neurosurg. 2021 Jul;151:e943-e949. doi: 10.1016/j.wneu.2021.05.023. Epub 2021 May 18.
Meningiomas are the most frequent primary brain tumors. The long-term natural history of asymptomatic meningiomas remains unclear and difficult to predict accurately, however. The purpose of this study was to determine the subsequent course of asymptomatic meningiomas preceded by 5 years of no treatment.
We retrospectively studied patients with radiologically suspected intracranial asymptomatic meningiomas preceded by 5 years of no treatment. We volumetrically measured the lesions' chronological changes during the initial 5 years to obtain the 5-year tumor doubling time (5y-TdT).
A total of 201 cases met the inclusion criteria. They were further divided into 3 subgroups: those who remained asymptomatic (group A; 174 cases), those who developed neurological symptoms and underwent treatment (group B; 8 cases), and those who received intentional intervention for a preventative reason (group C; 19 cases). 5y-TdT of group B (median: 46.5 months) was significantly shorter than that of group A (median: 216.3 months) (P < 0.001). Progression-free survival (PFS) was significantly different between tumors that exhibited 5y-TdT ≥ 98.8 months and <98.8 months (P < 0.001). When we combined groups B and C and set the PFS endpoint as either disease progression or treatment, we found that more than 20% of patients would require treatment within 15 years.
The present study revealed the subsequent course of asymptomatic meningiomas after 5 years of no treatment and demonstrated that 5y-TdT is useful to detect patients who may require treatment.
脑膜瘤是最常见的原发性脑肿瘤。然而,无症状脑膜瘤的长期自然史仍不清楚,也难以准确预测。本研究旨在确定 5 年无治疗史的无症状脑膜瘤的后续病程。
我们回顾性研究了影像学怀疑有颅内无症状脑膜瘤且 5 年无治疗史的患者。我们对病变的时间变化进行了容积测量,以获得 5 年肿瘤倍增时间(5y-TdT)。
共有 201 例符合纳入标准。他们进一步分为 3 个亚组:无症状患者(组 A;174 例)、出现神经症状并接受治疗的患者(组 B;8 例)和因预防性原因接受干预的患者(组 C;19 例)。组 B 的 5y-TdT(中位数:46.5 个月)明显短于组 A(中位数:216.3 个月)(P<0.001)。无进展生存期(PFS)在 5y-TdT≥98.8 个月和<98.8 个月的肿瘤之间有显著差异(P<0.001)。当我们将组 B 和组 C 合并,并将 PFS 终点设为疾病进展或治疗时,我们发现超过 20%的患者在 15 年内需要治疗。
本研究揭示了 5 年无治疗史后无症状脑膜瘤的后续病程,并表明 5y-TdT 有助于检测需要治疗的患者。